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RESEARCH ARTICLE Open Access
The association between ethnicity, stigma,
beliefs about medicines and adherence in
people living with HIV in a rural area in
Indonesia
E. I. Sianturi1,2* , D. A. Perwitasari3, Md. A. Islam1,4 and K. Taxis1
Abstract
Background: Indonesia is one of Asia’s countries with the fastest growing rate of human immunodeficiency virus
(HIV) infections according to the World Health Organization (WHO). The prevalence of HIV infections in the province
of Papua is 2.4% which is 24 times higher than the national rate in Indonesia. This study aimed to investigate the
association between stigma, beliefs about medicines, sociodemographic characteristics including ethnicity and
adherence in People living with HIV (PLHIV) in Papua, Indonesia.
Methods: We conducted a cross-sectional study using questionnaires. We included participants from two hospital-
outpatient clinics who were on antiretroviral treatment (ART) for more than 6 months, were at least 18 years old,
and signed informed consent. Participants completed the Medication Adherence Rating Scale (MARS), Beliefs about
Medicines Questionnaire (BMQ), an HIV stigma scale and questions on demographic information. Data on
antiretroviral medications were collected from medical records. The outcome was self-reported adherence as
measured by the MARS using an 80% cut-off score. Multivariate logistic regression was used to analyse the data.
Results: Overall, 331 out of 363 eligible participants were included with a mean age of 33.3 (± 9.4) years, 61.6%
were female, 67.1% were Papuan. A total of 65.9% of participants were adherent. Being Papuan decreased the
likelihood of adherence (odds ratio (OR) = 0.53; 95% confidence interval (CI) = 0.32–0.89). Feeling more distant, a
stigma type, also decreased the likelihood of adherence (OR = 0.93; 95% CI = 0.88–0.99).
Conclusion: The ethnicity of being Papuan and taking a distance to others were associated with non–adherence.
Targeted interventions should be developed to improve adherence in this group.
Keywords: HIV, Adherence, Stigma, Beliefs, Indigenous, Indonesia
Background
More than 36 million people who are infected with the
human immunodeficiency virus (HIV) worldwide re-
quire antiretroviral therapy (ART) to reduce mortality
and the number of new HIV infections [1]. ART is a life-
time medication and adherence to treatment is necessary
to be effective [2]. Based on a definition by the World
Health Organization (WHO), we understand adherence
to be the extent to which a person’s behavior in taking
medication corresponds with agreed recommendations
from a health care provider [3]. Stigma, family responsi-
bilities, and problems with schedule and routine have
been recognized as barriers to adherence [4].
Stigma is understood as a society’s attitude in disgra-
cing a person or group [5]. Feeling stigmatized is very
common in people living with HIV (PLHIV). PLHIV can
notice the stigma resulting in marginalizing behavior to-
wards the PLHIV [6]. It has been shown that stigmatized
PLHIV were less able to manage their disease [7]. Previ-
ous studies have also shown that stigma was a significant
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predictor for a lower level of ART adherence in develop-
ing and developed countries [8].
Beliefs about Medicines is a concept of cognitive
representation of medicines which has been introduced
by Horne et al. [9]. They developed a questionnaire to
quantify people’s beliefs of the necessity of taking medi-
cations versus concerns about adverse effects. In particu-
lar, having concerns about adverse effects and not being
convinced of the necessity of the medicines have been
found to be associated with non-adherence to ART [10].
Providing information and communicating about the
complexity of ART and possible adverse effects may
improve adherence [11].
Papua is the easternmost island of Indonesia. In the
province of Papua, the majority of the population are
indigenous Papuans. Ethnic non-Papuans are migrants
from other Indonesian islands, mostly to seek employ-
ment. Indonesia is one of Asia’s countries with the fast-
est growing rate of HIV infections according to the
Indonesian Ministry of Health and WHO. The preva-
lence of HIV infections in the province of Papua is 2.4%
which is 24 times higher than the national rate in
Indonesia. Of the 25.000 people living with acquired
immune deficiency syndrome (AIDS) in Papua [12], less
than 6000 PLHIV are on ART [13]. The main mode of
transmission is through unprotected sex between hetero-
sexuals [12]. In contrast to other areas in Indonesia,
most of the inhabitants of Papua are Christians.
In 2014, the Indonesian government set the strategic
target to have 80% of PLHIV covered by ART over 5
years [14]. This may effectively decrease the epidemic.
Maintaining adherence to ART has been regarded as a
major component to achieve this goal. A number of
studies have investigated the level of ART adherence in
Indonesia, but so far, these merely covered urban cities
in Indonesia with a different sociodemographic and
epidemiological context to Papua [15, 16]. Only one
Indonesian study explored the effect of stigma, again in
an urban population not using a validated scale to
assess stigma [16]. As far as we are aware, beliefs about
medicines have not been studied systematically in
Indonesia. Understanding which factors are associated
with low medication adherence is the base to develop
interventions to improve treatment of HIV in rural
areas like Papua [17].
This study aimed to investigate the association be-
tween stigma, beliefs about medicines, sociodemographic
characteristics including ethnicity and adherence in
people living with HIV in Papua, Indonesia.
Methods
Study design, setting and participants
This was a cross-sectional study using questionnaires to
assess stigma, beliefs about medicines and adherence to
medication. The participants were recruited from the
outpatient clinics of one public hospital and one private
hospital in Jayapura. These are two out of three hospitals
providing HIV care in Jayapura. We have selected those
two hospitals as they were the first ones to provide HIV
care by teams of specialists for 10 years. ART is dis-
pensed free of charge to patients.
Participants were included if they were at least 18
years old, were on ART for more than six months, and
signed informed consent. Patients were excluded if more
than 50% of data was missing. Participants were re-
cruited and informed about the study while they were
collecting their ART in the hospital. The recruiters, one
pharmacist and three nurses who were health care pro-
fessionals from the two HIV study hospitals, explained
the aim of the study. They also emphasized that all in-
formation was kept confidential and that the decision
whether to participate or not did not affect their treat-
ment in any way. After the participants signed the
informed consent, an appointment to complete the
questionnaires was made for the following month as part
of their next visit to the hospital.
The sample size was calculated based on the use of a
two tailed test with a level of significance of 0.05. It was
assumed that approximately 77% of the population were
adherent [16]. Therefore, at least 284 participants were
required to conduct the study.
Instruments
We have chosen to assess adherence [18], beliefs about
medicines [9] and stigma [19] with widely used instru-
ments [10, 20, 21].
Adherence
We used the self–reported Medication Adherence
Rating Scale (MARS) [18]. This consists of 10 questions.
This questionnaire assessed the patients’ medication
taking behavior in the past week. An example of a state-
ment is: “I take my medication only when I am sick”.
The response is binary, yes/no. A total MARS score is
calculated as the sum of all items with a maximum score
of 10 [18]. A higher total score indicated higher levels of
adherence. We dichotomized the response into adher-
ence and non-adherence. Sensitivity analyses were per-
formed with MARS scores of 7, 8 and 9 as the cut-off
(Additional file 1: Appendix). The cut-off score of 8 was
the most sensitive and was therefore used for the
analysis.
HIV stigma
The HIV Stigma-Sowell scale consists of 13 questions.
These 13 items represent 3 types of stigma, namely
distancing, blaming and discrimination [22]. A question
representing distancing is: “I thought other people were
Sianturi et al. BMC Public Health           (2019) 19:55 Page 2 of 8
uncomfortable being with me”. A question representing
blaming is: “I felt I would not get good health care if
people knew about my illness”. A question representing
discrimination is: “I felt compelled to change my resi-
dence because of my illness”. Answers are scored on a 4
point Likert scale (as: 1 = not at all, 2 = rarely, 3 = some-
times and 4 = often.) The distancing and blaming scales
were assessed with 4 questions each. The discrimination
scale was assessed with 5 questions. The total score
ranges from 13 to 52 with a higher total score indicating
a higher level of stigma.
Beliefs about medicines questionnaire (BMQ)
The BMQ assesses patient’s concepts about medication
use in general and patient’s beliefs about the medication
they use [9]. The BMQ-General part of the question-
naire consists of two scales asking about their views on
overuse and harm related to medication (four questions
each). An example of a statement on overuse is: “doctors
use too many medicines”. An example of a statement on
harm is: “most medicines are addictive.” The BMQ-Spe-
cific part consists of two scales about the necessity and
concerns of patients regarding their medicine (5 ques-
tions each). An example of a statement on necessity is:
“my antiretroviral medication protects me from
becoming worse”. An example of a statement on con-
cern is: “I am sometimes worried about becoming too
dependent on antiretroviral medication”. All 18 state-
ments were scored on a 5-point Likert scale as 1 =
strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, 5
= strongly agree. The total from every scale of the BMQ
was calculated. Higher total scores on necessity indicated
patients being positive and seeing the advantages taking
their medication. Higher total scores on concern, overuse,
and harm indicated concerns about the treatment.
Translation
Since all instruments were developed and validated in
English, we translated the instruments forwards into
Bahasa Indonesia and backwards into English. The for-
ward translation was done by two Indonesian certified
translators. Both versions were assessed by DPA as
proofreader and reviewer with a lot of experience in
translating questionnaires. A final, reconciled Bahasa
version was agreed on. This version was back-translated
by an English native speaker who had no information
about the original versions of the questionnaires. The
backward translation was modified several times because
the target language does not recognize verb tenses [23].
Therefore, the final version included words related to
time. The final questionnaires were tested in 67 PLHIV
who did not participate in the main study. The Cron-
bach’s alpha coefficient to test the internal consistency of
the questionnaires was: 0.94 for the MARS scale, 0.82
for the HIV stigma scale and 0.6 for the BMQ scale,
indicating good to moderate consistency. Participants
indicated they understood the questionnaires.
Data collection
At the appointment, participants were handed out the
three paper-based questionnaires and were also given a
questionnaire to collect sociodemographic information
(age, gender, marital status, whether or not they had
children, education, employment, sexual orientation,
religion, ethnicity, receiving support in medicine-taking
from social network, and ART regimen). They com-
pleted the questionnaires in the waiting area of the
hospital. The recruiters were available for questions.
Information about the age and types of ART were
collected from PLHIV’s medical records. Data were
collected between September and November 2016.
Descriptive statistics
The sociodemographic variables were analyzed using
descriptive statistics. The categorical variables were pre-
sented as frequencies and percentages. The continuous
variables were summarized either as mean (standard
deviation) or median (interquartile range) depending on
the nature of the variables. The outcome variable was
binary coded as non-adherent and adherent. Chi-square
test for categorical and independent sample t-test or
Mann-Whitney U test were used to determine the asso-
ciation between the independent variables and adher-
ence. We included the following independent variables
in the analyses: age, gender, marital status, having
children, education, employment, sexual orientation,
religion, ethnicity, social support in medicine-taking,
ART regimen, distancing, blaming and discrimination of
the stigma scale and necessity, concern, overuse and
harm from the BMQ questionnaire.
Statistical modelling
We included all independent variables with a p value of
< 0.20 in the descriptive analysis in a univariate logistic
regression to examine the effect of the independent
variables on adherence. Then, independent variables
with a p value of < 0.20 from the univariate analysis were
included in the multivariate logistic regression analysis
[24]. In the multivariate logistic regression analysis, we
used a backward elimination procedure to select the
final model with all independent variables being signifi-
cant with a p value of ≤0.05. Finally, odds ratios of inde-
pendent variables and their 95% confidence interval
were presented. All analyses were done using two-tailed
tests at a significance level of 0.05. The statistical ana-
lyses were performed using the Statistical Program for
Social Sciences (SPSS) version 24.0 for Windows.
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(n = 113; 34.1%)
Adherent
(n = 218; 65.9%)
p-value
Age (mean, SD) 33.3 (9.4) 31.3 (9.4) 34.3 (9.2)
18–27 years 43 (38.1) 53 (24.3) 0.019
28–37 years 44 (38.9) 91 (41.7)
Above 38 years 26 (23.0) 74 (33.9)
Gender 0.202
Female 204 (61.6) 75 (66.4) 129 (59.2)
Male 127 (38.4) 38 (33.6) 89 (40.8)
Marital Status 0.331
Not-married 104 (31.4) 31 (27.4) 73 (33.5)
Married 200 (60.4) 70 (61.9) 130 (59.6)
Divorced/widowed 27 (8.2) 12 (10.6) 15 (6.9)
Having Children 0.259
No 101 (30.5) 30 (26.5) 71 (32.0)
Yes 230 (69.5) 83 (73.5) 147 (67.4)
Education 0.309
Elementary school 7 (2.1) 1 (0.9) 6 (2.8)
Junior high school 28 (8.5) 7 (6.2) 21 (9.6)
High school 70 (21.1) 30 (26.5) 40 (18.3)
Vocational 171 (51.7) 57 (50.4) 114 (52.3)
University 8 (2.4) 4 (3.5) 4 (1.8)
Master 47 (14.2) 14 (12.4) 33 (15.1)
Employment 0.076
Unpaid 139 (42.0) 55 (48.7) 84 (38.5)
Paid 192 (58.0) 58 (51.3) 134 (61.5)
Sexual Orientation 0.335
Homosexual 9 (2.7) 1 (0.9) 8 (3.7)
Bisexual 3 (0.9) 1 (0.9) 2 (0.9)
Heterosexual 319 (96.4) 111 (98.2) 208 (95.4)
Religion 0.464
Protestant 247 (74.6) 88 (77.9) 159 (72.9)
Catholic 22 (6.6) 8 (7.1) 14 (6.4)
Moslim 62 (18.7) 17 (15.0) 45 (20.6)
Ethnicity 0.023
Non-Papuan 109 (32.9) 28 (24.8) 81 (37.2)




No support 113 (34.1) 43(38.1) 70 (32.1)
Support 218 (65.9) 70 (61.9) 148 (67.9)
Regimen 0.248
Duv-EFV 9 (1.2) 1 (0.9) 8 (3.7)
Duv-NEV 29 (2.7) 7 (6.2) 22 (10.1)
FDC 144 (43.5) 48 (42.5) 96 (44.0)
TDF-3TC-Aluvia 2 (0.6) 1 (0.9) 1 (0.5)
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Results
Study population
We identified 1305 PLHIV starting ART since 2006, suc-
cessfully contacted and screened 923 PLHIV of whom
388 were eligible. Finally, 363 participants agreed to sign
the informed consent and completed the questionnaire
(response rate 93%). Thirty-two participants had to be
excluded. Two participants were excluded because on
inspection of their medical records, they were below 18
years of age and 30 participants were excluded because
of missing sociodemographic data. Finally, 331 partici-
pants were eligible for data analysis.
Sociodemographic characteristics of participants
The mean age of participants was 33.3 years (SD = 9.4),
61.6% were female and 67.1% had a Papuan ethnicity.
Almost all participants were educated (51.7% had a vo-
cational and 21.1% had a high school education). More
than half of the participants (58.0%) reported having
paid employment. The majority (96.4%) were heterosex-
ual, 0.9% were bisexual, and 2.7% were gay. The majority
reported Protestantism as their religion (74.6%). A fixed
dose combination (FDC) was used as a single tablet
ART by 43.5% of all participants. The majority of partici-
pants (65.9%) received support in medicine-taking from
their social network (Table 1).
Overall, 65.9% of participants reported to be adher-
ent. There were no significant differences in gender,
marital status, having children, education, employ-
ment, sexual orientation, religion, and type of regimen
between non-adherent and adherent participants. Sig-
nificant differences were observed in age and ethnicity
between adherent and non-adherent participants
(Table 1).
Table 2 shows that the most common reasons for be-
ing non-adherent were forgetting to take ART (72.1%),
carelessly taking ART (51.4%) and attitudes towards
medication (55.9%). The difference between domain of
BMQ and Stigma scale compared to adherence were
shown in Table 3.
Multivariate logistic regression
Ethnicity and distancing were significantly associated
with adherence (Table 4). The sociodemographic fac-
tors (age and employment) and the other independ-
ent variables (blaming, concern, and harm) were not
associated with adherence. Papuans had half the
odds of being adherent than non-Papuans (OR =
0.53; 95% CI = 0.32–0.89). Feeling distanced also de-
creased the odds of being adherent (OR = 0.93; 95%
CI = 0.88–0.99).




(n = 113; 34.1%)
Adherent
(n = 218; 65.9%)
p-value
TDF-3TC-EFV 59 (17.8) 18 (15.9) 41 (18.8)
TDF-3TC-NEV 10 (3.0) 2 (1.8) 8 (3.7)
TDF-FTC-Aluvia 3 (0.9) 1 (0.9) 2 (0.9)
TDF-FTC-EFV 70 (21.1) 33 (29.2) 37 (17.0)
TDF-FTC-NEV 1 (0.3) 0 (0.0) 1 (0.5)
*SD Standard Deviation, Duv Duviral, EFV Efavirenz, NEV Nevirapine, FDC Fixed Dose Combination (TDF + 3TC + Efavirenz), TDF Tenofovir, 3TC Lamivudine,
FTC Emtricitabine
*p value according to Chi square test
Table 2 Medication Adherence Rating Scale (MARS) questionnaire (N = 113 non-adherent participants)
No The MARS question Frequency of responses indicating non-adherence (%)
N (%)
1 Do you ever forget to take your medication? 80 72.1
2 Are you careless at time about taking your medication? 57 51.4
3 When you feel better, do you sometimes stop taking your medication? 40 36.0
4 Sometimes if you feel worse when you take the medication, do you stop taking it? 33 29.7
5 I take medication only when I am sick 39 35.1
6 It is unnatural for my mind and body to be controlled by medication 62 55.9
7 My thoughts are clear on medication 31 27.9
8 By staying on medication, I can prevent getting sick 33 29.7
9 I feel weird, like a “zombie” on medication 45 40.5
10 Medication makes me feel tired and sluggish 43 38.7
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Discussion
This cross-sectional study showed that based on
self-reporting, more than one-third of PLHIV in Papua,
Indonesia were non-adherent. This was lower than in
another Indonesian study performed in an urban area
[16], but results are difficult to compare because of dif-
ferences in methods and instruments used. In line with
previous studies, the main reasons for non-adherence
were forgetfulness, being careless about taking ART,
and experiencing adverse effects [25]. Ethnicity and
experiencing stigma were significantly associated with
non-adherence.
Strength and Limitation.
This was the first study to examine ART adherence in
a predominantly heterosexual group of PLHIV living in
rural Indonesia where data is scarce. We recruited
participants when they came to pick up their medica-
tion, in one region in two hospitals in Indonesia with
about 10 years of experience to care for HIV patients.
Our data may not be generalizable to other settings and
regions. For practical reasons, we used hospital health
care professionals to recruit patients. We assured pa-
tients that participation was voluntary, but some
patients may have felt obliged to participate. We used
questionnaires and achieved the sample size needed.
The study also presents some caveats that need to be
discussed. We chose self-reporting to assess adherence.
Giving socially desirable answers and recall-bias are
among the disadvantages of this method [26]. It was out-
side the scope of this cross-sectional study to use other
methods. The two study hospitals used paper-based
medical records and there were insufficient data avail-
able to calculate adherence using for example refill rates.
Previous studies suggest that in PLHIV, self-reporting is
a suitable method [27]. We used the MARS question-
naire that has been developed and validated in
Table 3 Medians and IQR for the scales used to assess participant’s stigma, and Beliefs about Medicines (BMQ) comparing non-
adherent with adherent
Variable Lowest-Highest obtainable score Non-adherence Median (IQR) Adherence Median (IQR) Mann-Whitney U test
Stigma Scale
Distancing Median (IQR) 4.0–16.0 9.0 (6.0–11.5) 8.0 (4.0–11.0) 0.03
Blaming Median (IQR) 4.0–16.0 9.0 (6.0–10.5) 7.0 (5.0–10.0) 0.03
Discrimination Median (IQR) 5.0–20.0 11.0 (8.0–13.5) 10.0 (7.0–13.0) 0.24
Total Stigma 13.0–52.0 27.0 (20.0–35.0) 25.0 (19.0–34.0)
BMQ Scale
Necessity Median (IQR) 5.0–25.0 18.0 (16.0–20.0) 18.0 (16.0–20.0) 0.62
Concern Median (IQR) 5.0–25.0 16.0 (14.0–19.0) 16.0 (14.0–18.0) 0.05
Overuse Median (IQR) 4.0–20.0 12.0 (10.0–14.0) 12.0 (10.0–14.0) 0.48
Harm Median (IQR) 4.0–20.0 10.0 (8.0–12.0) 9.0 (8.0–11.0) 0.06
Total BMQ 18.0–90.0 57.0 (52.0–62.0) 55.0 (50.0–60.0)
*IQR Inter Quartile Range






Age 18–27 years ref
28–37 years 1.67 (0.97–2.87) 0.060
≥ 38 years 2.30 (1.26–4.21) 0.006
Ethnicity Non-Papuan ref ref
Papuan 0.55 (0.33–0.92) 0.024 0.53 (0.32–0.89) 0.017
Employment Unpaid ref
Paid 1.51 (0.96–2.39) 0.077
Stigma Distancing 0.94 (0.88–1.00) 0.058 0.93 (0.88–0.99) 0.040
Blaming 0.93 (0.87–1.00) 0.053
BMQ Concern 0.95 (0.88–1.01) 0.155
Harm 0.94 (0.87–1.01) 0.135
*OR Odds Ratio, CI Confidence Interval
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schizophrenia patients [18] and the use in PLHIV so far
was limited [28]. Therefore, a cut-off point for non-ad-
herence has not been defined previously. In our study,
PLHIV had to achieve a score of at least 8 out of 10 to
be adherent. This is relatively high compared to studies
in mental health. We chose this cut-off after using sensi-
tivity analysis. This cut-off point is acceptable to be used
since there is small difference between using 80 and 90%
adherence due to virological failure [29]. Finally, the
available data were insufficient to investigate the associ-
ation between adherence and clinical proxy outcomes
such as CD4 counts or viral load. In our setting, those
outcomes are infrequently assessed because of lack of
resources.
Ethnic group was found to be associated with adher-
ence. Being Papuan increased the likelihood of being
non-adherent. One of the reasons for this could be the
difficulties in communication between health profes-
sionals and PLHIV. Most of the health professionals are
non-Papuans and therefore do not speak the local
language. This is consistent with another study which
revealed that miscommunication between PLHIV and
health providers decreased the satisfaction with treat-
ment due to lack of psychological support from health
providers [30]. It also caused emotional stress and feel-
ing of discomfort due to loss of self-confidence [31]. The
most recognized complaints of PLHIV about physicians
are related to communication, not clinical competencies
[30]. More work is needed to investigate reasons for
non-adherence in Papuans. Our findings highlight the
importance to investigate the impact of ethnicity on
health care in Indonesia which has 300 ethnic groups, in
other regions with a similar mix of ethnicities.
The second result of this study found that stigma, as
assessed by the HIV stigma scale, was a significant factor
to diminish adherence for PLHIV [8]. Only one of the
HIV stigma subscales, feeling more distant, was associ-
ated with non-adherence whereas blame and discrimin-
ation were not significant. Experiencing stigma could
lead to fear to lose one’s companion, and this may result
in avoiding treatment hence non-adherence [22]. PLHIV
may try to isolate themselves from others in an attempt
to protect themselves as a way to cope with the stress of
having an HIV infection [32].
In contrast to other studies, the adherent and the
non-adherent group were similar in their responses
on the BMQ [10]. They perceived a relatively high
necessity for ART, but also relatively high concerns
and worries about overuse and harmful effects. The
decision to take ART may not be based on the ratio
of risk and benefit of ART alone, but other factors
such as stigma were also important. We also found
that the difference between the necessity and concern
scores were positive for both groups. It means PLHIV
were more positive about their medication than they
feared to experience adverse effects.
Our results have practical implications for health
providers. The first step should be to address communi-
cation barriers between health providers and Papuans.
Good communication skills may be essential to achieve
this. More Papuan social workers from religious institu-
tions may help Papuan PLHIV to solve the miscommu-
nication issues. Overall, more work is needed to
disentangle the reasons of why Papuans are more likely
to be non-adherent.
Distancing, one type of stigma also needs to be ad-
dressed. Clinical strategies may be less successful without
changing behavior associated with stigma in society.
Awareness about existing stigma may help health profes-
sionals to understand patients. Addressing non-adherence
may need a tailored intervention based on PLHIV’s needs.
Ultimately, health providers are recommended to be active
not only to discuss possible adverse effects but also to talk
about stigma-related issues with PLHIV. Collaboration be-
tween health providers and social workers may encourage
the patient’s family to be active in reducing distance by
providing more information about HIV. Psychological
consultations for PLHIV to learn accepting their HIV
status should also be available. Such interventions may
lead to increased self-esteem of stigmatized PLHIV to
not isolate themselves and actively visit health centers
without hesitation.
Conclusion
In conclusion, self-reported adherence was relatively low
in PLHIV in Papua, Indonesia. Ethnicity of being Pap-
uan, and feeling distant from others because of their
HIV status were associated with non–adherence. Tar-
geted interventions should be developed to improve ad-
herence in this PLHIV group.
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(DOCX 16 kb)
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